CMS identifies Medicare billing codes for combination antibody therapy

Hospital News

The Centers for Medicare & Medicaid Services has identified Healthcare Common Procedure Coding System codes for billing Medicare for the combination monoclonal antibodies bamlanivimab and etesevimab, made by Eli Lilly and Co.

The Food and Drug Administration this month authorized administering the monoclonal antibodies together to treat patients 12 and older with mild-to-moderate COVID-19 who are at high risk for progressing to severe disease but not hospitalized or on oxygen therapy. The emergency use authorization also authorizes the treatment for patients 65 or older with certain chronic medical conditions.

Products You May Like

Articles You May Like

House committee discusses future of telehealth
Podcast: Chicago hospital improves maternal and newborn health through strengthened community connections
Hospital-backed housing brings positive social return on investment: Health Affairs
Becerra’s HHS secretary bid moves forward on tie committee vote
Trinity’s Chicago Mercy Hospital enters deal to avert closing doors